Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney

被引:53
作者
Fujihara, CK [1 ]
Antunes, GR [1 ]
Mattar, AL [1 ]
Andreoli, N [1 ]
Malheiros, DMAC [1 ]
Noronha, IL [1 ]
Zatz, R [1 ]
机构
[1] Univ Sao Paulo, Fac Med, Dept Clin Med, Div Renal, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
prostaglandin-endoperoxide synthase; anti-inflammatory agents; nonsteroidal; kidney failure; chronic; kidney; inflammation; cyclooxygenase-2; glomerulosclerosis; renal ablation;
D O I
10.1046/j.1523-1755.2003.00319.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. The pathogenesis of progressive nephropathies involves hemodynamic and inflammatory factors. In the 5/6 nephrectomy model, a selective increase of cyclooxygenase-2 (COX-2) expression was shown, whereas treatment with a nonsteroidal anti-inflammatory or a specific COX-2 inhibitor was renoprotective. We investigated in the 5/6 nephrectomy model (1) the renal distribution of COX-2; (2) the hemodynamic and cellular mechanisms by which chronic COX-2 inhibition prevents renal injury. Methods. After 5/6 nephrectomy, adult male Munich-Wistar rats were subdivided in two groups: 5/6 nephrectomy (N = 20), receiving vehicle, and 5/6 nephrectomy + celecoxib (N = 19), treated orally with the COX-2 inhibitor, celecoxib, 10 mg/kg/day. Untreated and treated (celecoxib) sham-operated rats were also studied. Renal hemodynamics were examined at 4 weeks, whereas renal orphologic/immunohistochemical studies were carried at 8 weeks. Results. At 4 weeks, 5/6 nephrectomy rats exhibited marked systemic and glomerular hypertension. Celecoxib attenuated both systemic and glomerular hypertension, without affecting glomerular filtration rate (GFR). At 8 weeks, glomerulosclerosis and interstitial expansion were evident in 5/6 nephrectomy rats, and markedly attenuated in 5/6 nephrectomy rats given celecoxib. In both sham-operated and 5/6 nephrectomy rats, COX-2 was expressed at the macula densa. The extent of COX-2 expression at the macula densa was nearly tripled by celecoxib, indicating the existence of a feedback mechanism. In 5/6 nephrectomy rats, COX-2 was also expressed in glomeruli, arterioles, and the cortical interstitium, mostly at inflamed or sclerosing areas. Celecoxib markedly attenuated renal injury, inflammation, and ectopic COX-2 expression in 5/6 nephrectomy rats. Conclusion. Chronic COX-2 inhibition attenuated progressive nephropathy by reducing glomerular hypertension, renal inflammation, and ectopic COX-2 expression, indicating a complex contribution of COX-2 to progressive renal injury in 5/6 nephrectomy rats.
引用
收藏
页码:2172 / 2181
页数:10
相关论文
共 53 条
[1]  
Abbate M, 1998, J AM SOC NEPHROL, V9, P1213
[2]   Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis [J].
Anderson, GD ;
Hauser, SD ;
McGarity, KL ;
Bremer, ME ;
Isakson, PC ;
Gregory, SA .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (11) :2672-2679
[3]   DISTRIBUTION OF CYCLOOXYGENASE ISOFORMS IN MURINE CHRONIC GRANULOMATOUS INFLAMMATION - IMPLICATIONS FOR FUTURE ANTIINFLAMMATORY THERAPY [J].
APPLETON, I ;
TOMLINSON, A ;
MITCHELL, JA ;
WILLOUGHBY, DA .
JOURNAL OF PATHOLOGY, 1995, 176 (04) :413-420
[4]  
Becker BN, 1998, EXP NEPHROL, V6, P57
[5]   A SPECIFIC ENDOTHELIN SUBTYPE-A RECEPTOR ANTAGONIST PROTECTS AGAINST INJURY IN RENAL-DISEASE PROGRESSION [J].
BENIGNI, A ;
ZOJA, C ;
CORNA, D ;
ORISIO, S ;
LONGARETTI, L ;
BERTANI, T ;
REMUZZI, G .
KIDNEY INTERNATIONAL, 1993, 44 (02) :440-444
[6]  
BRENNER BM, 1985, AM J PHYSIOL, V249, P324
[7]   THROMBOXANE STIMULATES SYNTHESIS OF EXTRACELLULAR-MATRIX PROTEINS INVITRO [J].
BRUGGEMAN, LA ;
HORIGAN, EA ;
HORIKOSHI, S ;
RAY, PE ;
KLOTMAN, PE .
AMERICAN JOURNAL OF PHYSIOLOGY, 1991, 261 (03) :F488-F494
[8]  
Carroll M A, 2001, Med Sci Monit, V7, P567
[9]  
Castrop H, 2001, J AM SOC NEPHROL, V12, P867, DOI 10.1681/ASN.V125867
[10]   CYCLOOXYGENASE-1 AND CYCLOOXYGENASE-2 EXPRESSION IN RHEUMATOID SYNOVIAL TISSUES - EFFECTS OF INTERLEUKIN-1-BETA, PHORBOL ESTER, AND CORTICOSTEROIDS [J].
CROFFORD, LJ ;
WILDER, RL ;
RISTIMAKI, AP ;
SANO, H ;
REMMERS, EF ;
EPPS, HR ;
HLA, T .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (03) :1095-1101